Evelo Biosciences, Inc. unveiled Phase II data on 27 September indicating that its small intestinal axis-directed (SINTAX) therapeutic candidate EDP1815 can provide statistically significant clearance of psoriasis in mild-to-moderate cases with the safety profile of a placebo. The Cambridge, MA-based firm, a Flagship Pioneering portfolio company, says its SINTAX approach is differentiated from other microbiome therapies and may offer a new modality in immunology and other therapeutic areas.
The 249-patient study tested one-, four- and 10-capsule regimens of EDP1815 – an oral biologic that contains a single microbial strain optimized for pharmacological properties – against placebo in mild-to-moderate...